| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 13.07. | Insilico's Chinese partner returns for $177M pact to explore 'mass market' CNS indication | ||
| 10.07. | GSK sees phase 3 win for Hansoh-partnered ADC in China as validating its 'priority asset' | ||
| 10.07. | Bausch + Lomb gives up on glaucoma eye drop hopeful after phase 2 fail | ||
| 09.07. | Roche ends 2 Huntington's disease programs, including Ionis-partnered tominersen | ||
| 09.07. | Fate's off-the-shelf CAR-T therapy shows early promise in treatment-resistant autoimmune disease | ||
| 09.07. | GSK cuts losses on $700M upfront Alzheimer's collab with Alector following 2 clinical failures | ||
| 08.07. | Prime wins patent fight with Beam to continue work on AATD gene editing therapy | ||
| 08.07. | Satellos' 'intriguing' Duchenne data raise hopes ahead of key readout | ||
| 08.07. | Scipher picks up Chemomab's rheumatoid arthritis drug, Nasdaq listing in all-stock merger | ||
| 08.07. | AstraZeneca pens $2.1B Sino deal for challenger to Merck's COPD drug Ohtuvayre | ||
| 07.07. | MeiraGTx scores $400M from Oberland Capital to help get 2 gene therapies to commercialization | ||
| 07.07. | Whitehawk swoops in for five ADCs via development deal with China's Biocytogen | ||
| 07.07. | Boehringer bags PVT's viral vector platform for cancer vaccine R&D | ||
| 07.07. | As US lawmakers increase scrutiny of Chinese trials, industry fears 'huge distraction and expense' | ||
| 07.07. | Endevica spinout Kalohexis submits confidential IPO filing to develop obesity challenger to GLP-1s | ||
| 07.07. | Kailera's oral GLP-1 asset sees 11% weight loss, hits goals in Chinese phase 3 obesity and diabetes trials | ||
| 06.07. | Novartis to pay $1.1B upfront for UK biotech Myricx to expand the pharma's ADC pipeline | ||
| 03.07. | United Therapeutics pays $140M for thymic cell therapy startup | ||
| 03.07. | AstraZeneca pens $1.7B kidney drug discovery pact with go-to Chinese partner CSPC | ||
| 02.07. | Fosun pays $32M to join Lilly and Novartis in fiercely competitive psoriasis market | ||
| 02.07. | Roche orchestrates phase 3 KRAS lung cancer win over Amgen, BMS | ||
| 01.07. | Merck halts ph. 2 Alzheimer's trial after Neuphoria small molecule underwhelms | ||
| 01.07. | Ipsen gets the Memo, penning €700M deal to buy rare disease biotech for clinical-stage asset | ||
| 01.07. | Backed by top-tier VCs, stealthy biotech bags AlzeCure Alzheimer's asset in $2.2B deal | ||
| 30.06. | Bain-backed bone specialist Angitia drops lead spinal fusion candidate |